MB-101 received orphan drug designation for treating recurrent diffuse astrocytomas and glioblastoma, supporting rare disease treatments affecting fewer than 200,000 people in the U.S. Combining ...
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data ...
Mustang Bio, Inc. announced that its IL13Ra2-targeted CAR T-cell therapy, MB-101, received Orphan Drug Designation from the FDA for treating recurrent diffuse and anaplastic astrocytomas and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results